首页> 美国卫生研究院文献>other >The Prognostic Impact of Preoperative and Postoperative Chemoradiation in Clinical Stage II and III Esophageal Squamous Cell Carcinomas
【2h】

The Prognostic Impact of Preoperative and Postoperative Chemoradiation in Clinical Stage II and III Esophageal Squamous Cell Carcinomas

机译:术前和术后放化疗对ⅡⅢ期食管鳞癌的临床预后影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

While preoperative chemoradiation followed by surgery (pre-OP CRT) has been widely applied in the treatment of patients with esophageal cancer, some studies have shown a survival benefit of postoperative chemoradiation (post-OP CRT). The optimal combination of multimodality therapy and the sequence of surgery and chemoradiation for esophageal cancer remain to be investigated.A total of 1385 patients with clinical stage II and III esophageal squamous cell carcinoma (ESCC) were included. On the basis of the sequence of surgery and chemoradiation, the patients were grouped as follows: preoperative chemoradiation followed by surgery (pre-OP CRT+S), surgery alone (S), and surgery followed by postoperative chemoradiation (S+post-OP CRT). Propensity score matching analysis was used to identify 78 well-balanced patients in each group for outcome comparison.In all, 753, 339, and 293 patients were in the pre-OP CRT+S, S, and S+post-OP CRT groups, respectively. Before matching, no differences were observed in the overall survival among the patients in these 3 groups (P = 0.422). After matching, both the pre-OP CRT+S and S+post-OP CRT groups were significantly associated with a better survival compared with the S group (pre-OP CRT+S vs. S: P < 0.001; S+post-OP CRT vs. S: P = 0.005). In contrast, the survival was similar between the pre-OP CRT+S and S+post-OP CRT groups (P = 0.544). In the subgroup analysis, patients with clinical T3/4 stage tumors or those with a tumor size greater than 5 cm were more likely to demonstrate an overall survival benefit from pre-OP CRT compared with post-OP CRT.Both pre-OP CRT and post-OP CRT demonstrated a survival benefit compared with surgery alone, which indicates the importance of trimodality therapy in patients with clinical stage II/III ESCC. However, no survival difference was observed among patients in the pre-OP CRT+S and S+post-OP CRT groups, which suggests that the sequence of surgery and chemoradiation may be irrelevant to the outcome.
机译:术前放化疗后再进行手术(OP CRT前)已被广泛用于食管癌患者的治疗,但一些研究表明,术后放化疗(OP CRT后)具有生存优势。食管癌的多模式治疗以及手术和化学放疗顺序的最佳组合仍有待研究。共纳入了1385例临床II和III期食管鳞状细胞癌(ESCC)患者。根据手术和化学放疗的顺序,将患者分为以下几类:术前放化疗,然后进行手术(术前CRT + S),单独进行手术(S),然后手术后进行化学放疗(S +术后,OP) CRT)。倾向评分匹配分析用于确定每组78例平衡良好的患者,以进行结局比较.OP CRT前,S和S + OP后CRT组总共有753、339和293名患者, 分别。在匹配之前,这三组患者的总体生存率没有差异(P = 0.422)。匹配后,OP前CRT + S和S + OP后CRT组均显着高于S组(OP CRT + S vs. S:P <0.001; S +后OP CRT与S:P = 0.005)。相反,术前CRT + S组和术后S +术后CRT组的生存率相似(P = 0.544)。在亚组分析中,与手术后CRT相比,临床T3 / 4期肿瘤或肿瘤大小大于5 cm的患者更有可能证明手术前CRT的总体生存获益。与单独手术相比,OP CRT后显示出生存获益,这表明三联疗法在II / III期ESCC临床患者中的重要性。然而,术前CRT + S和术前S + CRT组患者之间没有观察到生存差异,这表明手术和化学放疗的顺序可能与结果无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号